Overview:
Influenza as an illness can cause
severe complications and mess up anybody's medical history. Influenza is of
various types and with a variety of deadly symptoms. Hence, early diagnosis of
influenza can reduce the chances of further complications. Therefore, with
World Health Organization (WHO) confirming about 600 million Influenza cases
worldwide, the services offering accurate Influenza diagnosis are going to be
in-demand always and become a part of a huge market in the medical sector.
Market Research Future (MRFR) has
published a report about the global Influenza Diagnostics Market. This
report expects 5.8% CAGRduring the forecast period between 2017 and 2023. In
terms of cash, this market is expected to grow with US $ 700.7 mn by 2023. This
report analyzes the market, potential for growth during the forecast period, market sizes around the world,
key players in the market, product
launches and latest research and development (R&D). The global influenza
diagnostics market is on the basis of types, tests,and region.The segmentation of types comprises of type A flu, type B flu, type C flu. The three forms
of type A are bird flu, seasonal flu, andSwine
flu. On the basis of direct fluorescent antibody (DFA) tests, molecular tests,
nucleic acid sequence-based amplification (NASBA) tests, rapid influenza
detection tests (RIDT), serological assays, simple amplification-based assays
(SAMBA) and loop-mediated isothermal amplification-based assays (LAMP).
Serological assays are segmented into primary serological tests, secondary
serological tests, and tertiary serological tests. Primary serological tests
cover enzyme-linkedimmunosorbent assay
(ELISA), immunofluorescent antibody
technique (IFAT) and radioimmunoassay
(RIA). Secondary Serological tests include agglutination tests, complement
fixation tests (CFT), precipitation tests, serum neutralization tests (SNT) and
toxin-antitoxin test.
The regional segmentation of the global influenza diagnostics market is into the
Americas (North America & South
America), Europe, Asia Pacific, and Middle East & Africa (MEA). North America is believed to be the largest market for
global influenza diagnostics due to advanced healthcare facilities andthe
increasing presence of major market
players in this region. Compared to North America, South America is a moderately smaller market,but that is not
due to lack of demand but due to the lack of awareness, lack of advanced
technology and lesser budgets for healthcare. In North America, the largest
markets are Canada and the United States of America (USA). After North America,
Europe is the largest market for influenza diagnostics. Here due to reasons
same as North America, Western Europe stands with the lion's share in Europe
market, compared to Eastern Europe. In Western Europe, the biggest markets are France, Germany, Italy,
Spain and the United Kingdom (UK), followed by the rest of Europe. During the forecast period, Asia Pacific region is
expected to experience large-scale growth
of influenza diagnostics market with China, India, Japan and South Korea
emerging as major markets. Remarkable growth is also expected in remaining
countries of Asia Pacific region. However, compared to the Asia Pacific, MEA is expected to have limited
growth, with Egypt, Saudi Arabia and the United
Arab Emirates (UAE) emerging as the best bets for Influenza
Diagnostics Market investors.The low market in the MEA
region is primarily due to the lack of
technology and education.
Key Players
The key players
in global influenza diagnostics market include Alere (USA), BD (USA), Becton
Dickinson (USA), BioMérieux SA (France), Cepheid (USA), Hardy Diagnostics(USA),
LifeSign LLC.(USA), Meridian Bioscience, Inc.(USA), Quidel Corporation (USA),
Roche Molecular Systems Inc.(Switzerland), and Sekisui Diagnostics (USA).
Latest Industry
News
·
Medical
technology company Becton Dickinson (BD), currently a key player in global
influenza diagnostics market, has formally
opened a new research facility at Plassey Technological Park in Limerick. This
business expansion has created 85 new jobs at its Irish operations. Currently,
BD employs more than 1,300 employees in Ireland across Drogheda, Dun Laoghaire
and its two sites in Limerick.
US-based leading molecular diagnostics
company, Cepheid Inc, a key player in global influenza diagnostics market, has
unveiled its newest configuration in the GeneXpert family of systems, the
GeneXpert Edge. An owned subsidiary of
Danaher, Cepheid Inc, also announced its ‘Make in India’ initiative regarding
which they have plans to establish their manufacturing footprint in the country
for Xpert MTB/RIF test cartridges which run on the GeneXpert System. In the last
two years, more than 1,200 Cepheid’s GeneXpert Systems have been
installed at various revised national
tuberculosis control program (RNTCP) sites in India. Last year, more
than 2.5 million cartridges were supplied at various centers of Central TB Division (CTD). The India launch of GeneXpert
Edge is expected later this year.
Access Full Report Details @ https://www.marketresearchfuture.com/reports/influenza-diagnostics-market-3142
No comments:
Post a Comment